查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1579375

抗逆转录病毒药物市场：按药物类别、给药途径、应用、分销管道划分 - 全球预测 2025-2030

Anti-Retroviral Drugs Market by Drug Class: (Entry Inhibitors, Fixed-dose Combinations, Integrase Inhibitors), Route of Administration (Intravenous, Oral, Subcutaneous), Application, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年抗逆转录病毒药物市值为278.2亿美元，预计2024年将达290.5亿美元，复合年增长率为4.59%，到2030年将达到381.2亿美元。

抗逆转录病毒药物市场范围主要包括旨在预防爱滋病毒（导致爱滋病的病毒）复製的药物。这些药物的需求源于它们在减少病毒量、改善免疫功能以及降低与爱滋病毒感染相关的发病率和死亡率方面的重要作用。抗逆转录病毒药物主要用于管理和治疗爱滋病毒感染者，最终使用者包括医院、诊所和居家医疗机构。市场成长主要是由于人们对爱滋病毒和早期治疗重要性的认识提高、政府倡议、对爱滋病毒/爱滋病计画的资助以及旨在提高疗效和减少副作用的药物配方技术进步而推动的。最新的潜在机会在于开发长效注射疗法和联合治疗，以提高患者的依从性和结果。此外，新兴市场中爱滋病毒流行率的不断上升带来了巨大的成长机会。然而，该市场面临着治疗费用高、潜在副作用以及确保低收入地区药品分配的可及性和公平性等挑战。生技药品的监管障碍和复杂的製造流程也对市场扩张构成了重大挑战。为了克服这些障碍，创新应着重于降低製造成本和改善基础设施以实现更广泛的分销。适合创新的研究领域包括用于靶向药物传输的奈米技术、用于客製化治疗的个人化医疗方法以及利用人工智慧加速药物发现。该市场的特点是竞争激烈，少数主要企业大力投资研发和策略联盟以保持主导地位。总体而言，策略重点是扩大服务不足地区的获取机会并持续专注于创新治疗解决方案，这将寻求利用抗逆转录病毒药物领域的成长机会，这对于参与企业至关重要。

主要市场统计
基准年[2023] 278.2亿美元
预测年份 [2024] 290.5亿美元
预测年份 [2030] 381.2亿美元
复合年增长率（%） 4.59%

市场动态：揭示快速发展的抗逆转录病毒药物市场的关键市场洞察

供需的动态交互作用正在改变抗逆转录病毒药物市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 透过采用学名药抗逆转录病毒药物引入具有成本效益的治疗方案
    • 扩大新兴国家的医疗基础设施和可近性
    • 整合数位医疗技术以改善病患管理和依从性
  • 市场限制因素
    • 接受抗逆转录病毒治疗的耻辱和社会障碍
  • 市场机会
    • 透过整合抗逆转录病毒治疗和个人化医疗来改善患者的治疗效果
    • 加速儿科抗逆转录病毒的开发，以解决治疗缺口
    • 加强官民合作关係，加速抗逆转录病毒药物市场的研发
  • 市场问题
    • 监理合规严格、核准程序复杂

波特五力：驾驭抗逆转录病毒药物市场的策略工具

波特的五力架构是了解抗逆转录病毒药物市场竞争格局的重要工具。波特的五力框架描述了评估公司竞争和探索策略机会的清晰方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点，避免潜在的挑战，确保更强大的市场地位。

PESTLE分析：了解抗逆转录病毒病毒药物市场的外部影响

外部宏观环境因素在塑造抗逆转录病毒病毒药物市场的表现动态发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解抗逆转录病毒病毒药物市场的竞争格局

抗逆转录病毒药物市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、细分和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵抗逆转录病毒病毒药物市场供应商的绩效评估

FPNV定位矩阵是评估抗逆转录病毒药物市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘抗逆转录病毒药物市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，抗逆转录病毒药物市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

该报告对涵盖关键焦点细分市场的市场进行了全面分析。

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有细分市场的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

它也回答重要问题，帮助相关人员做出明智的决策。

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品和地区提供最佳投资机会？

3.塑造市场的关键技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 采用非专利抗逆转录病毒药物创造了具有成本效益的治疗选择
      • 扩大新兴经济体的卫生基础设施和服务机会
      • 整合数位医疗技术以改善病患管理和依从性
    • 抑制因素
      • 接受抗逆转录病毒治疗的耻辱和社会障碍
    • 机会
      • 透过整合抗逆转录病毒治疗和个人化医疗来改善患者的治疗效果
      • 加速儿科抗逆转录病毒的开发以填补治疗空白
      • 抗逆转录病毒药物市场加强公私合营并促进研究和开发
    • 任务
      • 监理合规严格、核准程序复杂
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 经济
    • 社会
    • 科技
    • 法律
    • 环境

第六章抗逆转录病毒药物市场：依药物类别

  • 介绍
  • 进入抑制剂
  • 固定剂量组合
  • 整合酶抑制剂
  • 非核苷类逆转录酶抑制剂
  • 核苷逆转录酶抑制剂
  • 蛋白酶抑制剂

第七章抗逆转录病毒药物市场：依途径

  • 介绍
  • 静脉
  • 口服
  • 皮下的

第八章抗逆转录病毒药物市场：依应用分类

  • 介绍
  • 爱滋病毒治疗
  • 暴露后预防
  • 暴露前预防

第九章抗逆转录病毒药物市场：依分销管道划分

  • 介绍
  • 医院药房
  • 网路药房
  • 零售药房

第十章美洲抗逆转录病毒药物市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太地区抗逆转录病毒药物市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章 欧洲、中东和非洲抗逆转录病毒药物市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • FDA核准Dovato 用于治疗 12 岁及以上 HIV 感染者，标誌着治疗和依从性方面取得重大进展
    • Zydus Lifesciences 的非专利地芦那韦片获得美国FDA核准
  • 战略分析和建议
    • Cipla Limited

公司名单

  • AbbVie Inc.
  • Alkem Laboratories Ltd.
  • APOTEX INC.
  • Aurobindo Pharma Limited
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Hetero Drugs Limited
  • Janssen Pharmaceuticals, Inc. by Johnson & Johnson
  • Jubilant Life Sciences Limited
  • Lupin Limited
  • MacroGenics, Inc.
  • Merck & Co., Inc.
  • Mylan Laboratories by Viatris Inc.
  • Mylan NV
  • Novartis AG
  • Pfizer Inc.
  • Roche Holding AG
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
  • ViiV Healthcare
Product Code: MRR-1A1A064C02F2

The Anti-Retroviral Drugs Market was valued at USD 27.82 billion in 2023, expected to reach USD 29.05 billion in 2024, and is projected to grow at a CAGR of 4.59%, to USD 38.12 billion by 2030.

The scope of the anti-retroviral drugs market primarily encompasses medications designed to prevent the replication of HIV, the virus that causes AIDS. The necessity of these drugs stems from their critical role in reducing viral load, improving immune function, and decreasing morbidity and mortality associated with HIV infection. Applications of anti-retroviral drugs are primarily in the management and treatment of HIV-infected individuals, with end-users including hospitals, clinics, and home care settings. Market growth is heavily influenced by increasing awareness about HIV and the importance of early treatment, government initiatives, and funding for HIV/AIDS programs, coupled with technological advancements in drug formulations for improved efficacy and reduced side effects. The latest potential opportunities lie in developing long-acting injectable treatments and combination therapies that improve patient adherence and outcomes. Additionally, the growing prevalence of HIV in emerging markets presents substantial growth opportunities. However, the market faces limitations such as high costs of treatment, potential side effects, and challenges in ensuring accessibility and equity in drug distribution in low-income regions. Regulatory hurdles and the complex manufacturing process of these biologics also pose significant challenges to market expansion. To overcome these barriers, innovation should focus on reducing production costs and improving infrastructure for broader distribution. Research areas ripe for innovation include nanotechnology for targeted drug delivery, personalized medicine approaches for tailored treatments, and leveraging AI to accelerate drug discovery. The market is characterized by intense competition, with a few dominant players investing heavily in R&D and strategic collaborations to maintain their leadership position. Overall, a strategic emphasis on expanding access in underserved regions, coupled with a sustained focus on innovative therapeutic solutions, will be essential for market participants seeking to leverage growth opportunities in the anti-retroviral drugs sector.

KEY MARKET STATISTICS
Base Year [2023] USD 27.82 billion
Estimated Year [2024] USD 29.05 billion
Forecast Year [2030] USD 38.12 billion
CAGR (%) 4.59%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Anti-Retroviral Drugs Market

The Anti-Retroviral Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Introduction of generic antiretroviral drugs leading to cost-effective treatment options
    • Expanding healthcare infrastructure and accessibility in emerging economies
    • Integration of digital health technologies for better patient management and adherence
  • Market Restraints
    • Stigma and social barriers limiting the uptake of anti-retroviral therapies
  • Market Opportunities
    • Integration of anti-retroviral therapies with personalized medicine for improved patient outcomes
    • Accelerating development of pediatric anti-retroviral formulations to address treatment gaps
    • Enhancing public-private partnerships to boost research and development in the anti-retroviral drugs market
  • Market Challenges
    • Stringent regulatory compliance and complex approval procedures

Porter's Five Forces: A Strategic Tool for Navigating the Anti-Retroviral Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Anti-Retroviral Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Anti-Retroviral Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Anti-Retroviral Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Anti-Retroviral Drugs Market

A detailed market share analysis in the Anti-Retroviral Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Anti-Retroviral Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Anti-Retroviral Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Anti-Retroviral Drugs Market

A strategic analysis of the Anti-Retroviral Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Anti-Retroviral Drugs Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Alkem Laboratories Ltd., APOTEX INC., Aurobindo Pharma Limited, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Cipla Limited, Dr. Reddy's Laboratories Ltd., Gilead Sciences, Inc., GlaxoSmithKline plc, Hetero Drugs Limited, Janssen Pharmaceuticals, Inc. by Johnson & Johnson, Jubilant Life Sciences Limited, Lupin Limited, MacroGenics, Inc., Merck & Co., Inc., Mylan Laboratories by Viatris Inc., Mylan N.V., Novartis AG, Pfizer Inc., Roche Holding AG, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., and ViiV Healthcare.

Market Segmentation & Coverage

This research report categorizes the Anti-Retroviral Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Class:, market is studied across Entry Inhibitors, Fixed-dose Combinations, Integrase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Nucleoside Reverse Transcriptase Inhibitors, and Protease Inhibitors.
  • Based on Route of Administration, market is studied across Intravenous, Oral, and Subcutaneous.
  • Based on Application, market is studied across HIV Treatment, Post-exposure Prophylaxis, and Pre-exposure Prophylaxis.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Introduction of generic antiretroviral drugs leading to cost-effective treatment options
      • 5.1.1.2. Expanding healthcare infrastructure and accessibility in emerging economies
      • 5.1.1.3. Integration of digital health technologies for better patient management and adherence
    • 5.1.2. Restraints
      • 5.1.2.1. Stigma and social barriers limiting the uptake of anti-retroviral therapies
    • 5.1.3. Opportunities
      • 5.1.3.1. Integration of anti-retroviral therapies with personalized medicine for improved patient outcomes
      • 5.1.3.2. Accelerating development of pediatric anti-retroviral formulations to address treatment gaps
      • 5.1.3.3. Enhancing public-private partnerships to boost research and development in the anti-retroviral drugs market
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory compliance and complex approval procedures
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Anti-Retroviral Drugs Market, by Drug Class:

  • 6.1. Introduction
  • 6.2. Entry Inhibitors
  • 6.3. Fixed-dose Combinations
  • 6.4. Integrase Inhibitors
  • 6.5. Non-Nucleoside Reverse Transcriptase Inhibitors
  • 6.6. Nucleoside Reverse Transcriptase Inhibitors
  • 6.7. Protease Inhibitors

7. Anti-Retroviral Drugs Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Intravenous
  • 7.3. Oral
  • 7.4. Subcutaneous

8. Anti-Retroviral Drugs Market, by Application

  • 8.1. Introduction
  • 8.2. HIV Treatment
  • 8.3. Post-exposure Prophylaxis
  • 8.4. Pre-exposure Prophylaxis

9. Anti-Retroviral Drugs Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Hospital Pharmacies
  • 9.3. Online Pharmacies
  • 9.4. Retail Pharmacies

10. Americas Anti-Retroviral Drugs Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Anti-Retroviral Drugs Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Anti-Retroviral Drugs Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. FDA approval of Dovato for adolescents 12 and older living with HIV marks a significant breakthrough in treatment and adherence
    • 13.3.2. Zydus Lifesciences secures USFDA nod for generic Darunavir Tablets
  • 13.4. Strategy Analysis & Recommendation
    • 13.4.1. Cipla Limited

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Alkem Laboratories Ltd.
  • 3. APOTEX INC.
  • 4. Aurobindo Pharma Limited
  • 5. Boehringer Ingelheim GmbH
  • 6. Bristol-Myers Squibb Company
  • 7. Cipla Limited
  • 8. Dr. Reddy's Laboratories Ltd.
  • 9. Gilead Sciences, Inc.
  • 10. GlaxoSmithKline plc
  • 11. Hetero Drugs Limited
  • 12. Janssen Pharmaceuticals, Inc. by Johnson & Johnson
  • 13. Jubilant Life Sciences Limited
  • 14. Lupin Limited
  • 15. MacroGenics, Inc.
  • 16. Merck & Co., Inc.
  • 17. Mylan Laboratories by Viatris Inc.
  • 18. Mylan N.V.
  • 19. Novartis AG
  • 20. Pfizer Inc.
  • 21. Roche Holding AG
  • 22. Sun Pharmaceutical Industries Ltd.
  • 23. Teva Pharmaceutical Industries Ltd.
  • 24. Torrent Pharmaceuticals Ltd.
  • 25. ViiV Healthcare

LIST OF FIGURES

  • FIGURE 1. ANTI-RETROVIRAL DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. ANTI-RETROVIRAL DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES ANTI-RETROVIRAL DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES ANTI-RETROVIRAL DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. ANTI-RETROVIRAL DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. ANTI-RETROVIRAL DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ANTI-RETROVIRAL DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ANTI-RETROVIRAL DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ENTRY INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FIXED-DOSE COMBINATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INTEGRASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PROTEASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY HIV TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY POST-EXPOSURE PROPHYLAXIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PRE-EXPOSURE PROPHYLAXIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES ANTI-RETROVIRAL DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. AUSTRALIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 63. CHINA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. CHINA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 67. INDIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. INDIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 71. INDONESIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 72. INDONESIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 75. JAPAN ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 76. JAPAN ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 79. MALAYSIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. MALAYSIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 83. PHILIPPINES ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 84. PHILIPPINES ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 87. SINGAPORE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 88. SINGAPORE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH KOREA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 92. SOUTH KOREA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 95. TAIWAN ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. TAIWAN ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 99. THAILAND ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 100. THAILAND ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 103. VIETNAM ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 104. VIETNAM ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 112. DENMARK ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 113. DENMARK ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 116. EGYPT ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 117. EGYPT ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 120. FINLAND ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 121. FINLAND ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 124. FRANCE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 125. FRANCE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 128. GERMANY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 129. GERMANY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 132. ISRAEL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 133. ISRAEL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 136. ITALY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 137. ITALY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 140. NETHERLANDS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 141. NETHERLANDS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 144. NIGERIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 145. NIGERIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 148. NORWAY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 149. NORWAY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 152. POLAND ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 153. POLAND ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 156. QATAR ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 157. QATAR ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 160. RUSSIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 161. RUSSIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 164. SAUDI ARABIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 165. SAUDI ARABIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 169. SOUTH AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 172. SPAIN ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 173. SPAIN ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 176. SWEDEN ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 177. SWEDEN ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 180. SWITZERLAND ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 181. SWITZERLAND ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 184. TURKEY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 185. TURKEY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED ARAB EMIRATES ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED KINGDOM ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 193. UNITED KINGDOM ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 194. ANTI-RETROVIRAL DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 195. ANTI-RETROVIRAL DRUGS MARKET, FPNV POSITIONING MATRIX, 2023